Dr Fabio Schutz addresses a key challenge when treating patients with metastatic castration resistant prostate cancer (mCRPC). What do you do if they progress on an androgen receptor (AR) directed therapy?
Dr Fabio Schutz addresses a key challenge when treating patients with metastatic castration resistant prostate cancer (mCRPC). What do you do if they progress on an androgen receptor (AR) directed therapy?
Dr Fabio Schutz graduated from Parana Federal University and did his internal medicine residency at Hospital de Clinicas in Curitiba - PR, Brazil. Then, he moved to São Paulo - SP for his medical oncology clinical fellowship at Hospital Sirio Libanes. After finishing his medical oncology fellowship, he worked for a couple of years as an assistant medical oncologist in the same hospital. From 2009 to 2011, he worked as a research fellow in genitourinary (GU) oncology in the Lank Center for GU Oncology at the Dana-Farber Cancer Institute - Harvard Medical School in Boston - MA, USA. He developed several original research projects and authored many manuscripts in high-impact journals. Since mid-2011, he is working as a medical oncologist of the BP - Beneficencia Portuguesa de Sao Paulo in Sao Paulo - SP, Brazil. He is most interested and is currently conducting clinical trials in GU cancers.
Astellas, Bayer, BMS, Janssen and Ipsen
From sample collection through to diagnostic modalities
Medical experts discuss how to approach sequencing in clinical practice
Medical experts share their insights on testing and treatment
Medical experts discuss safety and efficacy of IO and IO combinations, clinical trial data, and best practice
Expert opinion on the clinical application of artificial intelligence (AI)
Medical experts share insights and review key clinical trials